Thermo Fisher Scientific (TMO) Gains from Investment Securities (2009 - 2026)

Thermo Fisher Scientific has disclosed Gains from Investment Securities across 18 years of filings, most recently posting -$88.0 million for Q1 2026.

• Quarterly Gains from Investment Securities rose 34.81% year-over-year to -$88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$408.0 million (down 353.33% YoY) and the FY2025 annual result came in at -$455.0 million, down 5587.5% from the prior year.
• Gains from Investment Securities rose to -$88.0 million in Q1 2026, from -$435.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $408.0 million in Q4 2023 and troughed at -$470.0 million in Q4 2022.
• A 5-year average of -$66.7 million and a median of -$88.0 million in 2026 frame the typical range for Gains from Investment Securities.
• Biggest YoY gain for Gains from Investment Securities was 204.17% in 2022; the steepest drop was 23600.0% in 2022.
• Tracing TMO's Gains from Investment Securities over 5 years: stood at -$470.0 million in 2022, then jumped by 186.81% to $408.0 million in 2023, then slumped by 39.71% to $246.0 million in 2024, then slumped by 276.83% to -$435.0 million in 2025, then jumped by 79.77% to -$88.0 million in 2026.
• Business Quant data shows TMO's Gains from Investment Securities at -$88.0 million in Q1 2026, -$435.0 million in Q4 2025, and $178.0 million in Q3 2025.